ArticleMedical oncology (Northwood, London, England)2026
Phytochemical and pharmacological elucidation of Jasonia glutinosa (L.) fourr. essential oil: a promising therapeutic source against inflammation and cancer.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Uncharted phytochemical frontiers: a systematic review of novel bioactive compounds from underexplored aromatic plants for cancer therapy.Frontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing demand for natural therapeutics with safer pharmacological profiles has renewed interest in aromatic plants traditionally used in folk medicine. Jasonia glutinosa (L.) Fourr. (Asteraceae), commonly known as "sticky fleabane", is a medicinal and aromatic species widely employed for its digestive and anti-inflammatory benefits. Despite its ethnopharmacological relevance, the bioactive potential of its essential oil remains poorly explored. This study provides a multifaceted investigation of the chemical composition, safety profile, and pharmacological activities of J. glutinosa essential oil (JGEO). Gas chromatography-mass spectrometry (GC-MS) analysis revealed nerolidol (51.29%) as the predominant constituent, accompanied by isoaromadendrene epoxide (17.39%) and cis-α-copaene-8-ol (9.92%). The genotoxicity assessment, conducted using the alkaline comet assay on rat leukocytes, demonstrated no significant DNA damage at concentrations up to 100 µg/mL, confirming the oil's genomic safety within the tested range. Pharmacological evaluation showed that JGEO exerted potent anti-inflammatory effects, significantly reducing nitric oxide (NO) and prostaglandin E₂ (PGE₂) production in LPS-stimulated macrophages - with NO levels decreasing to 18.4% of control values and PGE₂ from 720 µM to 108.2 µM (p < 0.001). Moreover, JGEO exhibited selective cytotoxicity against multiple human cancer cell lines, with IC₅₀ values of 15.43 µg/mL (MCF-7), 24.24 µg/mL (MDA-MB-468), 74.57 µg/mL (HCT-15), and 18.06 µg/mL (HepG2). Remarkably, high selectivity indices for MCF-7 (SI = 63.67) and HepG2 (SI = 54.40) surpassed those of doxorubicin, highlighting its favorable therapeutic window. Collectively, these findings provide a scientific basis for the traditional uses of J. glutinosa, emphasizing its safety, efficacy, and chemical richness. The study positions JGEO as a promising natural source of bioactive terpenoids for the development of anti-inflammatory and anticancer agents, supporting its further exploration in pharmaceutical and nutraceutical formulations.
Indexed as
Identifiers
41670759What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.